PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China · Delayed Price · Currency is CNY 42.40
-1.63 (-3.70%)
Sep 10, 2026, 3:04 PM CST
SHE:300725 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 10,258 | 8,983 | 6,681 | 7,841 | 16,073 | 28,391 | |
Market Cap Growth | 5.02% | 34.47% | -14.80% | -51.22% | -43.39% | 41.66% |
Enterprise Value | 8,651 | 8,183 | 7,577 | 8,455 | 16,316 | 27,695 |
Last Close Price | 44.03 | 38.14 | 32.97 | 38.13 | 78.02 | 137.63 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 46.76 | 48.89 | 30.43 | 39.73 | 51.15 | 58.35 |
Forward PE | 42.34 | 37.71 | 26.11 | 27.44 | 37.00 | 65.42 |
PS Ratio | 4.85 | 4.55 | 3.96 | 4.55 | 10.08 | 23.63 |
PB Ratio | 2.25 | 1.43 | 2.24 | 2.77 | 6.05 | 10.81 |
P/TBV Ratio | 2.50 | 1.54 | 2.65 | 3.31 | 7.34 | 14.49 |
P/FCF Ratio | 74.38 | 17.04 | 36.17 | - | - | - |
P/OCF Ratio | 26.11 | 13.46 | 22.06 | 31.77 | 65.18 | 119.28 |
PEG Ratio | - | 0.85 | 0.85 | 0.85 | 0.85 | 0.85 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.09 | 4.14 | 4.49 | 4.90 | 10.23 | 23.05 |
EV/EBITDA Ratio | 23.88 | 24.78 | 21.22 | 22.59 | 44.53 | 85.84 |
EV/EBIT Ratio | 39.84 | 41.87 | 33.48 | 32.53 | 58.23 | 102.79 |
EV/FCF Ratio | 62.72 | 15.52 | 41.03 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.02 | 0.47 | 0.62 | 0.59 | 0.14 |
Debt / EBITDA Ratio | 0.34 | 0.34 | 3.93 | 4.65 | 4.27 | 1.17 |
Debt / FCF Ratio | 0.88 | 0.21 | 7.66 | - | - | - |
Net Debt / Equity Ratio | -0.35 | -0.24 | 0.01 | 0.05 | -0.02 | -0.28 |
Net Debt / EBITDA Ratio | -4.48 | -4.57 | 0.11 | 0.40 | -0.12 | -2.24 |
Net Debt / FCF Ratio | -11.65 | -2.86 | 0.22 | -2.14 | 0.14 | 2.70 |
Asset Turnover | 0.39 | 0.32 | 0.34 | 0.35 | 0.38 | 0.41 |
Inventory Turnover | 2.04 | 1.87 | 1.41 | 1.45 | 1.56 | 1.67 |
Quick Ratio | 2.93 | 3.23 | 2.48 | 1.97 | 2.64 | 1.66 |
Current Ratio | 3.94 | 4.30 | 3.63 | 2.67 | 3.60 | 2.29 |
Return on Equity (ROE) | 5.14% | 3.96% | 7.54% | 7.19% | 12.33% | 22.28% |
Return on Assets (ROA) | 2.49% | 1.99% | 2.82% | 3.26% | 4.18% | 5.68% |
Return on Invested Capital (ROIC) | 5.18% | 4.42% | 6.65% | 8.29% | 12.41% | 21.04% |
Return on Capital Employed (ROCE) | 4.70% | 2.90% | 5.40% | 6.40% | 6.80% | 9.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.05% | 2.04% | 3.29% | 2.52% | 1.96% | 1.71% |
FCF Yield | 1.34% | 5.87% | 2.77% | -0.88% | -1.94% | -0.94% |
Dividend Yield | 0.47% | 0.73% | 0.85% | 0.81% | 0.13% | 0.07% |
Payout Ratio | 30.12% | 35.78% | 35.52% | 21.13% | 10.71% | 4.60% |
Buyback Yield / Dilution | -10.99% | -4.61% | 0.90% | -0.62% | -0.37% | -6.09% |
Total Shareholder Return | -10.52% | -3.88% | 1.75% | 0.19% | -0.24% | -6.02% |